Absci Corporation

NASDAQ:ABSI

Biotechnology

Healthcare
$8.18 +1.04%

+$0.08 today

Market cap
$1.41B
Beta
2.46
P/E (TTM)
-9.4
EPS (TTM)
-$0.77
52W Low $2.24High $8.17

Volume 5.66M

Average 5.10M

ABSI EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Absci CorporationNASDAQ: ABSI

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -$26.87M, compared with -$23.2M a year earlier. Trailing-twelve-month EBITDA was -$106.84M.

Context

  • EBITDA amounted to 3684.4% of revenue in FY2025, up 1609.0 pp from a year earlier.
  • EBITDA grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether EBITDA reaches the consensus estimate from 7 analysts of -$97.32M (+5.7%) for the fiscal year ending Dec 2026, a step up from the -9.6% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$26.87M-0.0% QoQ
Last fiscal yearDec 2025
-$103.16M-9.6% YoY
LTMMar 2026
-$106.84M-14.3% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-15.8%-10.0%+5.8 pp
1 year-9.6%+5.7%+15.3 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(103.16M) USD
Year-over-year change
-9.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How ABSI compares with its peers on the latest reported figures

  • ABSI's LTM Mar 2026 EBITDA of -$106.84M is the highest of the 3 companies compared; the peer median is -$173.57M.
  • Its year-over-year change of -14.3% is the 2nd highest of 3, against a peer median of +3.7%.
  • EBITDA amounts to 5818.9% of revenue for ABSI, versus a peer median of 429.0%.
ABSI Competitors Peer median
EBITDA for ABSI and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ABSIAbsci CorporationLTM Mar 2026-$106.84M -14.3%—5818.9%
ABCLAbCellera Biologics Inc.LTM Sep 2026-$138.65M +34.7%—204.3%
GENBGenerate Biomedicines, Inc.FY2025-$208.49M -27.4%—653.7%
Peer median (excluding ABSI) -$173.57M+3.7%—429.0%

Competitors are the stored peer set for ABSI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.78M5.75M5.72M4.53M2.8M
Cost of Revenue44.59M58.91M47.57M62.46M11.74M
Gross Profit(39.8M)(53.16M)(41.85M)(57.93M)(8.94M)
Gross Margin-832.4%-925.0%-731.9%-1277.6%-319.4%
Research & Development44.59M58.91M48.07M63.86M81.42M
Selling, General & Admin000035.06M
Operating Expenses35.43M53.59M73.67M50.96M115.78M
Depreciation & Amortization6.65M13.04M14M13.39M11.74M
EBITDA(67.68M)(91.36M)(79.68M)(94.1M)(103.16M)
EBITDA Margin-1415.4%-1589.6%-1393.5%-2075.4%-3684.4%
Operating Income(75.24M)(106.75M)(115.52M)(108.89M)(124.72M)
Operating Margin-1573.4%-1857.5%-2020.2%-2401.6%-4454.2%
Interest Income00000
Interest Expense3.43M972K1.01M565K209K
Other Income / Expenses(34.62M)1.39M5.05M5.85M9.6M
Income Before Tax(109.86M)(105.37M)(110.47M)(103.04M)(115.11M)
Pre-Tax Margin-2297.3%-1833.4%-1931.9%-2272.5%-4111.2%
Income Tax Expense(8.9M)(461K)100K70K69K
Net Income(100.96M)(104.9M)(110.57M)(103.11M)(115.18M)
Net Margin-2111.3%-1825.4%-1933.6%-2274.1%-4113.7%
EPS (Basic)(1.11)(1.15)(1.20)(0.94)(0.84)
EPS (Diluted)(1.11)(1.15)(1.20)(0.94)(0.84)
Weighted Avg Shares92.65M90.85M92.03M110.24M136.78M
Weighted Avg Shares (Diluted)92.65M90.85M92.03M110.24M136.78M

Absci Corporation

NASDAQ:ABSI

Intrinsic Alpha fair value

Locked

Current Price

$8.18

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.